Peptide Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Cancer, Metabolic Disorders, Cardiovascular Disorders, Respiratory Disorders, Gastrointestinal Disorders, Infectious Diseases, Pain, Dermatological Disorders, Neurological Disorders, Renal Disorders, Others), By Type (Generic, Innovative), By Type of Manufacturers (In-house, Outsourced), By Route of Administration (Parenteral Route, Oral Route, Pulmonary, Mucosal, Others), By Synthesis Technology (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology), By Region, and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 56.90 Billion
CAGR (2026-2031)	9.25%
Fastest Growing Segment	Metabolic Disorders
Largest Market	North America
Market Size (2031)	USD 96.73 Billion

Market Overview

The Global Peptide Therapeutics Market will grow from USD 56.90 Billion in 2025 to USD 96.73 Billion by 2031 at a 9.25% CAGR. Peptide therapeutics are selective signaling molecules composed of short amino acid chains that regulate specific physiological processes with high potency and reduced toxicity. The global market is expanding due to the rising incidence of chronic metabolic conditions, such as diabetes and obesity, which has intensified the demand for targeted receptor agonists. Furthermore, improvements in synthetic manufacturing processes are lowering production barriers and facilitating broader commercialization. According to the American Chemical Society, in 2023, nine peptide and oligonucleotide therapeutics were approved by the FDA, constituting 16% of all new drug approvals for that year.

However, the industry faces a substantial impediment related to drug delivery and stability. Peptides typically exhibit poor oral bioavailability and rapid clearance from the bloodstream due to enzymatic degradation, often necessitating frequent injections. This requirement for invasive administration routes poses a challenge to patient compliance and limits the wider adoption of peptide-based treatments in chronic disease management.

Key Market Drivers

The escalating global prevalence of metabolic and chronic diseases, specifically obesity and type 2 diabetes, serves as a primary engine for market growth. This rising disease burden has shifted clinical focus toward Glucagon-like peptide-1 (GLP-1) receptor agonists, which regulate appetite and insulin secretion with high efficacy. Consequently, leading pharmaceutical developers are witnessing exponential revenue surges from their metabolic peptide portfolios, necessitating increased production capabilities. According to Novo Nordisk, February 2024, in the 'Annual Report 2023', sales within the company’s Obesity Care division increased by 154% at constant exchange rates to 41.6 billion Danish kroner. This financial performance underscores the critical role of peptide therapeutics in managing chronic lifestyle conditions and validates the heavy commercial reliance on these targeted biological molecules.

Robust expansion of biopharmaceutical R&D and strategic alliances acts as the second critical driver, characterized by aggressive acquisitions aimed at securing novel peptide assets. Large pharmaceutical entities are increasingly purchasing specialized biotech firms to access next-generation dual and triple agonists, thereby mitigating early-stage development risks and accelerating time-to-market. According to Roche, December 2023, in the 'Roche enters into definitive merger agreement to acquire Carmot Therapeutics' press release, the corporation agreed to acquire the peptide drug developer for an upfront payment of 2.7 billion US dollars. Such high-value transactions highlight the industry commitment to expanding peptide pipelines beyond standard insulin therapies. Furthermore, manufacturers are heavily investing in infrastructure to meet this projected need. According to Eli Lilly and Company, November 2023, in the 'Lilly announces plans to invest 2.5 billion dollars' press release, the organization committed this sum to construct a new manufacturing site in Germany dedicated to expanding its parenteral peptide supply network.

Download Free Sample Report

Key Market Challenges

The primary impediment hampering the growth of the Global Peptide Therapeutics Market is the inherent instability of peptide molecules and the consequent challenges related to drug delivery. Peptides are susceptible to rapid enzymatic degradation in the gastrointestinal tract and bloodstream, which results in poor oral bioavailability and short half-lives. This instability necessitates the use of invasive administration routes, primarily subcutaneous or intravenous injections, to ensure the drug reaches its target with sufficient potency. The requirement for frequent injections creates a significant barrier to patient compliance, particularly for chronic diseases where long-term adherence is critical, thereby limiting the addressable patient population and reducing market penetration.

This complexity in formulating stable, effective delivery mechanisms also slows the pace at which new products can successfully navigate the regulatory pipeline. According to the Regulatory Affairs Professionals Society, in 2024, only two novel peptide therapeutics were granted FDA approval, representing just 4% of the 50 new molecular entities authorized that year. This low approval rate, compared to traditional small molecules, underscores the persistent difficulty developers face in overcoming stability issues, which directly restricts the volume of new therapies entering the market.

Key Market Trends

The integration of AI for Accelerated Peptide Discovery is fundamentally reshaping the R&D landscape by overcoming the traditional complexities of peptide design, such as optimizing membrane permeability and metabolic stability. Computational platforms are now enabling the rapid screening of vast virtual libraries to identify candidates with high binding affinity and favorable pharmacokinetic profiles before wet-lab synthesis begins. This technological shift allows developers to compress discovery timelines and reduce the high attrition rates associated with early-stage development. According to BioDuro, August 2025, in the 'Atombeat and BioDuro Announce Strategic Partnership' press release, the company deployed an AI-powered platform capable of analyzing over one trillion potential peptide compounds to expedite the identification of developable therapeutic candidates.

The Development of Next-Generation Peptide Drug Conjugates (PDCs) represents a significant evolution in targeted oncology, moving beyond simple receptor agonists to sophisticated delivery systems that transport cytotoxic or radioactive payloads directly to tumor cells. Unlike antibody-drug conjugates, PDCs offer deeper tissue penetration and faster systemic clearance, minimizing off-target toxicity while maintaining high potency against solid tumors. This trend is characterized by a surge in clinical activity focused on radioligand therapies and novel linker technologies that enhance stability in circulation. According to WuXi AppTec, June 2025, in the 'H1 2025 Update on Conjugated Therapeutics' report, the rapid expansion of this modality was evidenced by the initiation of more than 30 radioligand drug conjugate clinical trials in 2024, reflecting a threefold increase compared to five years prior.

Segmental Insights

The Metabolic Disorders segment currently represents the most rapidly expanding area within the Global Peptide Therapeutics Market. This trajectory is primarily driven by the surging adoption of Glucagon-like peptide-1 receptor agonists for treating type 2 diabetes and obesity. The United States Food and Drug Administration has recently expanded approvals for specific peptide therapies to include weight management indications, which has significantly broadened the addressable patient base. Consequently, the increasing global prevalence of chronic metabolic conditions combined with continued regulatory support establishes this therapeutic class as the primary driver of market expansion.

Regional Insights

North America maintains a commanding position in the Global Peptide Therapeutics Market, driven by a mature biopharmaceutical infrastructure and extensive investment in research and development. The region benefits from a favorable regulatory climate, where the U.S. Food and Drug Administration (FDA) actively facilitates the approval of innovative peptide formulations. Furthermore, the high prevalence of chronic conditions, including metabolic disorders and cancer, propels the demand for targeted treatment options. This market leadership is further strengthened by the presence of major pharmaceutical companies and the adoption of advanced drug delivery technologies across the healthcare sector.

Recent Developments

• In November 2025, Biogen entered into a research collaboration with Dayra Therapeutics to discover and develop oral macrocyclic peptides for the treatment of immunological conditions. The agreement involved an upfront payment of $50 million to Dayra Therapeutics, with the potential for additional development and commercial milestone payments. The partnership aims to leverage a proprietary discovery platform to identify macrocyclic peptide candidates that combine biologic-like efficacy with the convenience of oral administration. Biogen stated that this initiative would significantly expand its early-stage pipeline by incorporating a clinically validated modality to target high-priority immunological diseases.
• In August 2025, BioMed X and Novo Nordisk launched a strategic research collaboration focused on the efficient oral delivery of therapeutic peptides. The partnership established a dedicated research group at the BioMed X Institute in Heidelberg, Germany, to work on a project titled "Prolonged Retention of Oral Peptide Formulations in the Gut." This initiative aims to develop novel formulation technologies that enable site-specific, prolonged retention of dosage forms in the small intestine. The companies intend to improve the absorption and bioavailability of peptide-based medicines, addressing a critical challenge in treating chronic conditions like obesity and diabetes.
• In August 2024, the U.S. Food and Drug Administration (FDA) approved Yorvipath (palopegteriparatide) for the treatment of hypoparathyroidism in adults. Developed by Ascendis Pharma, this new product is a prodrug of parathyroid hormone (PTH 1-34) designed to provide continuous exposure to the active hormone over a 24-hour period. The approval marked a significant milestone as the first and only TransCon peptide therapy indicated for this rare endocrine disorder. The company announced that the initial commercial supply of the medication would be made available to patients in the United States by the first quarter of 2025.
• In June 2024, Zealand Pharma announced positive topline results from a Phase 1b multiple ascending dose clinical trial of petrelintide. The study investigated the safety, tolerability, and clinical effects of this long-acting amylin analog, which is being developed for weight management. Participants receiving high doses of the peptide therapeutic achieved a mean body weight reduction of up to 8.6% after 16 weeks of weekly dosing. The company highlighted that the drug was safe and well-tolerated, with no anti-drug antibodies observed, supporting its potential as an effective alternative to GLP-1 receptor agonist therapies in the Global Peptide Therapeutics Market.

Key Market Players

• Eli Lilly and Co.
• Pfizer Inc.
• Amgen Inc.
• Takeda Pharmaceutical Co Ltd.
• AstraZeneca Pharmaceuticals LP
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• F Hoffmann-La Roche AG
• Novartis AG
• Novo Nordisk A/S

By Application	By Type	By Type of Manufacturers	By Route of Administration	By Synthesis Technology	By Region
Cancer Metabolic Disorders Cardiovascular Disorders Respiratory Disorders Gastrointestinal Disorders Infectious Diseases Pain Dermatological Disorders Neurological Disorders Renal Disorders Others	Generic Innovative	In-house Outsourced	Parenteral Route Oral Route Pulmonary Mucosal Others	Solid Phase Peptide Synthesis (SPPS) Liquid Phase Peptide Synthesis (LPPS) Hybrid Technology	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Peptide Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Peptide Therapeutics Market, By Application:

• Cancer
• Metabolic Disorders
• Cardiovascular Disorders
• Respiratory Disorders
• Gastrointestinal Disorders
• Infectious Diseases
• Pain
• Dermatological Disorders
• Neurological Disorders
• Renal Disorders
• Others

• Peptide Therapeutics Market, By Type:

• Generic
• Innovative

• Peptide Therapeutics Market, By Type of Manufacturers:

• In-house
• Outsourced

• Peptide Therapeutics Market, By Route of Administration:

• Parenteral Route
• Oral Route
• Pulmonary
• Mucosal
• Others

• Peptide Therapeutics Market, By Synthesis Technology:

• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

• Peptide Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE